2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(2-phenylethyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(2-phenylethyl)acetamide
• 化学式: C₁₈H₁₉NO₃
• 分子量: 297.3
• InChiKey: XADXOZSYUJQDNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BIASED AGONISTS OF OPIOID RECEPTORS
  申请人：ILDONG PHARMACEUTICAL CO., LTD.

  公开号：US20220204449A1

  公开（公告）日：2022-06-30

  The present disclosure provides pharmaceutical compositions and compounds having dual agonist activity at the μ and δ opioid receptors. The agonist compounds of this disclosure can also provide GPCR functional selectivity, including selective activity in the Gi pathway. In some embodiments, the compounds of this disclosure are biased μ-opioid and/or δ-opioid receptor agonists that do not significantly recruit β-arrestins, but can activate G-protein-dependent pathways, and thus can be administered without risk of significant undesirable side effects exhibited by conventional opioid receptor agonists. In some embodiments there is provided a substantially optically pure compound having dual agonist activity at the μ and δ opioid receptors.
• [EN] BIASED AGONISTS OF OPIOID RECEPTORS<br/>[FR] AGONISTES DE RÉCEPTEURS OPIOÏDES POLARISÉS
  申请人：[en]ILDONG PHARMACEUTICAL CO., LTD.

  公开号：WO2022123319A1

  公开（公告）日：2022-06-16

  The present disclosure provides pharmaceutical compositions and compounds having dual agonist activity at the μ and δ opioid receptors. The agonist compounds of this disclosure can also provide GPCR functional selectivity, including selective activity in the Gi pathway. In some embodiments, the compounds of this disclosure are biased μ-opioid and/or δ-opioid receptor agonists that do not significantly recruit β-arrestins, but can activate G- protein-dependent pathways, and thus can be administered without risk of significant undesirable side effects exhibited by conventional opioid receptor agonists. In some embodiments there is provided a substantially optically pure compound having dual agonist activity at the μ and δ opioid receptors.